92 related articles for article (PubMed ID: 20923533)
1. Insulin secretory function in type 2 diabetes: Does it matter how you measure it?
Reaven GM
J Diabetes; 2009 Sep; 1(3):142-50. PubMed ID: 20923533
[TBL] [Abstract][Full Text] [Related]
2. What is the effect of rosiglitazone treatment on insulin secretory function in insulin-resistant individuals? It depends on how you measure it.
Abbasi F; Lamendola C; Reaven GM
Metabolism; 2011 Jan; 60(1):57-62. PubMed ID: 20356610
[TBL] [Abstract][Full Text] [Related]
3. Beta-cell function and mass in type 2 diabetes.
Larsen MO
Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
[TBL] [Abstract][Full Text] [Related]
4. Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose.
Abdul-Ghani MA; Williams K; DeFronzo R; Stern M
Diabetes Care; 2006 Jul; 29(7):1613-8. PubMed ID: 16801587
[TBL] [Abstract][Full Text] [Related]
5. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels.
Utzschneider KM; Prigeon RL; Faulenbach MV; Tong J; Carr DB; Boyko EJ; Leonetti DL; McNeely MJ; Fujimoto WY; Kahn SE
Diabetes Care; 2009 Feb; 32(2):335-41. PubMed ID: 18957530
[TBL] [Abstract][Full Text] [Related]
6. HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not?
Reaven GM
Diab Vasc Dis Res; 2009 Apr; 6(2):133-8. PubMed ID: 20368203
[No Abstract] [Full Text] [Related]
7. Effects of weight loss and reduced hyperglycemia on the kinetics of insulin secretion in obese non-insulin dependent diabetes mellitus.
Gumbiner B; Polonsky KS; Beltz WF; Griver K; Wallace P; Brechtel G; Henry RR
J Clin Endocrinol Metab; 1990 Jun; 70(6):1594-602. PubMed ID: 2189885
[TBL] [Abstract][Full Text] [Related]
8. Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test.
Festa A; Williams K; Hanley AJ; Haffner SM
Diabetes; 2008 Jun; 57(6):1638-44. PubMed ID: 18332099
[TBL] [Abstract][Full Text] [Related]
9. Relationships between insulin secretion after intravenous and oral glucose administration in subjects with glucose tolerance ranging from normal to overt diabetes.
Mari A; Tura A; Pacini G; Kautzky-Willer A; Ferrannini E
Diabet Med; 2008 Jun; 25(6):671-7. PubMed ID: 18544104
[TBL] [Abstract][Full Text] [Related]
10. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.
Shapiro ET; Van Cauter E; Tillil H; Given BD; Hirsch L; Beebe C; Rubenstein AH; Polonsky KS
J Clin Endocrinol Metab; 1989 Sep; 69(3):571-6. PubMed ID: 2503533
[TBL] [Abstract][Full Text] [Related]
11. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
Henkel E; Menschikowski M; Koehler C; Leonhardt W; Hanefeld M
Metabolism; 2005 Sep; 54(9):1168-73. PubMed ID: 16125528
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of islet beta cell function in subjects with normal glucose tolerance, impaired glucose regulation, and type 2 diabetes mellitus].
Liu J; Li YB; Shao H; Li YX; Yuan YH; Xiao YB; Weng JP
Zhonghua Yi Xue Za Zhi; 2007 May; 87(18):1252-5. PubMed ID: 17686259
[TBL] [Abstract][Full Text] [Related]
13. [Role of insulin resistance and β cell function in the development of newly diagnosed type 2 diabetes].
Chen X; Su M; Wang C; Wu Z; Li S; Ying X; Wei G; Fu C; Jiang Q
Wei Sheng Yan Jiu; 2015 Nov; 44(6):881-6. PubMed ID: 26738376
[TBL] [Abstract][Full Text] [Related]
14. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance.
Reaven GM; Chen YD; Hollenbeck CB; Sheu WH; Ostrega D; Polonsky KS
J Clin Endocrinol Metab; 1993 Jan; 76(1):44-8. PubMed ID: 8421101
[TBL] [Abstract][Full Text] [Related]
15. Expanding the clinical use of standard OGTT: the percentage increment of 2 h with respect to fasting glucose as an index of β-cell dysfunction.
Carnevale Schianca GP; Mella R; Scaglia E; Bigliocca M; Colli E; Fra GP; Bartoli E
Diabetes Metab Res Rev; 2011 Mar; 27(3):262-8. PubMed ID: 21309049
[TBL] [Abstract][Full Text] [Related]
16. [Associations of insulin resistance and pancreatic beta-cell function with plasma glucose level in type 2 diabetes].
Nian X; Sun G; Dou C; Hou H; Fan X; Yu H; Ma L; He B
Zhonghua Yi Xue Za Zhi; 2002 Jun; 82(11):732-5. PubMed ID: 12126540
[TBL] [Abstract][Full Text] [Related]
17. Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study.
Gastaldelli A; Gaggini M; DeFronzo RA
Diabetes; 2017 Apr; 66(4):815-822. PubMed ID: 28052966
[TBL] [Abstract][Full Text] [Related]
18. Insulin resistance, β-cell dysfunction and differences in curves of plasma glucose and insulin in the intermediate points of the standard glucose tolerance test in adults with cystic fibrosis.
Cano Megías M; González Albarrán O; Guisado Vasco P; Lamas Ferreiro A; Máiz Carro L
Endocrinol Nutr; 2015 Feb; 62(2):91-9. PubMed ID: 25444978
[TBL] [Abstract][Full Text] [Related]
19. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.
Højberg PV; Vilsbøll T; Zander M; Knop FK; Krarup T; Vølund A; Holst JJ; Madsbad S
Diabet Med; 2008 Nov; 25(11):1268-75. PubMed ID: 19046215
[TBL] [Abstract][Full Text] [Related]
20. Impact of a mild decrease in fasting plasma glucose on β-cell function in healthy subjects and patients with type 2 diabetes.
Seghieri M; Rebelos E; Astiarraga BD; Baldi S; Mari A; Ferrannini E
Am J Physiol Endocrinol Metab; 2016 Jun; 310(11):E919-24. PubMed ID: 27072495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
